CN1172680C - Locally applied composite medicine for treating pointed condyloma - Google Patents
Locally applied composite medicine for treating pointed condyloma Download PDFInfo
- Publication number
- CN1172680C CN1172680C CNB021294380A CN02129438A CN1172680C CN 1172680 C CN1172680 C CN 1172680C CN B021294380 A CNB021294380 A CN B021294380A CN 02129438 A CN02129438 A CN 02129438A CN 1172680 C CN1172680 C CN 1172680C
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- composition according
- liniment
- podophyllotoxin
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a locally-applied medicinal composition for treating condyloma acuminatum, which comprises one or more medicines for destroying wart bodies and one or more local anaesthetics. Through adding the local anaesthetics in the medicinal composition, the irritation of the medicines can be reduced, and thus, the compliance of patients is enhanced.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition for the treatment of the topical of condyloma acuminatum.
Background technology
Condyloma acuminatum (CA) (claiming genital wart, sharp Gui wart or genital wart again) is that its treatment is removed focus based on the part by the epidermoma sample proliferation at genitals, perineum and anus position due to human papillomavirus (HPV) infection, and whole body therapeutic is auxilliary.
Medicine commonly used is podophyllotoxin, Pingyang toxin, 5-Fu, bleomycin A5, peptide butylamine, finds can produce bigger zest in application process in the use of these medicines, causes bigger misery to patient, and patient is reluctant to accept.
Summary of the invention
The purpose of this invention is to provide a kind of be used for the treatment of condyloma acuminatum and medicine irritation is little, and can increase the pharmaceutical composition of topical of patient's compliance.
For achieving the above object, the present invention adopts following technical scheme:
A kind of pharmaceutical composition that is used for the treatment of the topical of condyloma acuminatum destroys the medicine of wart bodies and one or more local anesthetics and pharmaceutical carrier by one or more and is formed.
The medicine of destruction wart body be in podophyllotoxin, Bleomycin A5,5-Fu, bleomycin A5 and the peptide butylamine one or more.The medicine that The present invention be more particularly directed to destroy the wart body is a podophyllotoxin, be the gamma therapy of nineteen ninety The World Health Organization's recommendation as genital wart, the choice drug as the treatment sexually transmitted disease (STD) was recommended by health ministry epidemic prevention department in 1994, unique selected medicine of " national essential drugs " skin class antiviral medication in 1994, its concentration by weight 0.1～5%.
Described local anesthetic is one or more in tetracaine, tetracaine, lignocaine, procaine and the benzocaine, can also be the anesthetis with the form of salt, and consumption is with by weight 0.1%～5.0%.Local anesthetic can be amide type local anesthetic such as aptocaine.Bupivacaine, butanilicaine, carticaine, cinchocaine, clibucaine are to piperidino acetaminobenzoic acid ester type local anesthetic, as benzocaine.
This pharmaceutical composition can be to contain one or more medicines that destroy the wart body and the ointment of one or more local anesthetics, can use conventional ointment base, comprises oleaginous base, emulsion-type substrate, aqueous matrix.Preferably the form of liniment contains medicine and one or more local anesthetics that one or more destroy the wart body.
Comprise polymer substance, plasticizer, The suitable solvent system in the substrate of described liniment.
Described plasticizer is a glycerol etc.
Described polymer substance comprises one or more in sodium alginate, polyvinylpyrrolidone (PVP) and the Polyethylene Glycol (PEG).
Described solvent comprises distilled water, ethanol or its mixture.
The invention has the advantages that: by in pharmaceutical composition, adding local anesthetic, can reduce medicine irritation, thereby increase patient's compliance.
The specific embodiment
Embodiment 1: compound recipe podophyllotoxin lignocaine liniment
Podophyllotoxin 2.0g
Lignocaine 1.0g
PVP(44-08) 1.0g
Glycerol 5.0g
Ethanol 60.0g
Distilled water adds to 100ml
Preparation method: by recipe quantity podophyllotoxin is dissolved in the ethanol, PVP, glycerol, the lignocaine of recipe quantity is dissolved in an amount of distilled water, the alcoholic solution of podophyllotoxin is slowly joined in the aqueous solution of PVP and glycerol, the limit edged stirs, mix homogeneously is diluted to prescribed volume, gets final product.Through checking this liniment to contain podophyllotoxin is 2.0wt%, contains lignocaine 1.0wt%.
Embodiment 2; Compound recipe podophyllotoxin lignocaine liniment
Podophyllotoxin 2.0g
Lignocaine 1.0g
Sodium alginate 8.0g
Glycerol 5.0g
Ethanol 60.0g
Distilled water adds to 100ml
Preparation method: podophyllotoxin is dissolved in the ethanol by recipe quantity, sodium alginate, glycerol, the lignocaine of recipe quantity are dissolved in an amount of distilled water, the alcoholic solution of podophyllotoxin is slowly joined in the aqueous solution of sodium alginate and glycerol, the limit edged stirs, mix homogeneously, be diluted to prescribed volume, get final product.Through checking this liniment to contain podophyllotoxin is 2.0wt%, contains lignocaine 1.0wt%.
Embodiment 3: compound recipe podophyllotoxin procaine liniment
Podophyllotoxin 20.0g
Procaine 20.0g
Hard ester acid 120g
Glycerol 100g
Tween 80 40ml
Octadecanol 50g
Potassium sorbate 3g
Vaseline 50g
Ethanol 60.0g
Distilled water 640ml
Preparation method: take by weighing stearic acid, octadecanol, the vaseline of recipe quantity respectively, mix, 80 ℃ add thawing, add the podophyllotoxin of recipe quantity, and the multilamellar filtered through gauze is used in dissolving, and is standby; Take by weighing the distilled water of 640ml, stir and make dissolving, add procaine, glycerol, Tween 80, stir evenly 80 ℃ of water bath heat preservations: the solid phase that will melt adds liquid phase water solution under constantly stirring, carry out emulsifying, is stirred to condensation and gets final product, and this product is an O/W type emulsifiable paste; Through check, this product content is that every 10g emulsifiable paste contains podophyllotoxin 0.2g, procaine 0.2g, and gained emulsifiable paste viscosity (insertion degree 271) is qualified, and coating has good uniformity.
Embodiment 4: the skin irritation test
Experimental animal: the big mortar rabbit (20 example) of Japan
Experimental technique: get compound recipe podophyllotoxin lignocaine liniment 0.5ml, evenly coat rabbit and do not have on the fur skin, observe in the 72h.
The result: show speckle edema etc. does not stimulate phenomenon.
Conclusion: nonirritant.
Embodiment 5: acute eye irritation test
Experimental animal: Japan large rabbit (20 example).
Test method: get compound recipe podophyllotoxin lignocaine liniment 0.1ml, slowly splash in the rabbit conjunctival of getting home, the about 1s of eyelid that gently sleeps then, an other eye does not deal with, in contrast.
The result: cornea, iris, to estimate film all normal, do not see any irritative symptoms.
Conclusion: nonirritant.
Embodiment 6: the local anesthesia experiment
Experimental animal: selecting body weight for use is male guinea pig about 300～350g, two every group, shave clean its back hair? one in the hair of positive middle front part skin all makes skin region exposed about 3cm2.
Test method: Cavia porcellus with the numb anesthesia of ether, is lied prostrate the position and is fixed on the operating-table.Damage this place's skin with the scratch method.With compound recipe podophyllotoxin lignocaine liniment, be applied to 10 minutes after, adopt the skin pain sensation reaction (thorn test place skin region has shrinkage phenomenon when remaining as the pain sensation) of lancing test agents area to compare different pharmaceutical pain sensation reaction times in the ratio of testing time, adopt distilled water as negative control simultaneously, 0.2% lidocaine ointment the results are shown in following table as positive control.
The local anesthesia result of the test
Testing time pain sensation reaction times ratio (%)
Compound recipe podophyllotoxin benefit 12 00
The caine liniment
Distilled water 12 12 100
Lidocaine ointment 12 2 16.7
Conclusion: compound recipe podophyllotoxin lignocaine liniment local anesthesia effect is obvious.
Clinical treatment observation, according to case 10 examples of random collecting, the result shows that use compound recipe podophyllotoxin lignocaine liniment obviously reduces single zest of using podophyllotoxin to cause, increases patient's compliance, patient is generally reflected well.
Claims (9)
1, a kind of pharmaceutical composition that is used for the treatment of the topical of condyloma acuminatum destroys the medicine of wart bodies and one or more local anesthetics and pharmaceutical carrier by one or more and is formed.
2, pharmaceutical composition according to claim 1 is characterized in that: the medicine of described destruction wart body is podophyllotoxin, Bleomycin A5,5-Fu, bleomycin A5 and peptide butylamine.
3, pharmaceutical composition according to claim 1 and 2 is characterized in that: described local anesthetic is tetracaine, tetracaine, lignocaine, procaine and benzocaine, and with the anesthetis of the form of salt.
4, pharmaceutical composition according to claim 3 is characterized in that: the content of medicines of described destruction wart body be 0.1wt%～～content of 5wt%, local anesthetic is that 0.1wt%～5.0wt%, surplus are pharmaceutical carrier.
5, pharmaceutical composition according to claim 4 is characterized in that: described pharmaceutical composition is a liniment, and described pharmaceutical carrier is that the substrate of liniment is polymer substance, plasticizer and solvent.
6, pharmaceutical composition according to claim 5 is characterized in that: described polymer substance is one or more in sodium alginate, polyvinylpyrrolidone (PVP) and the Polyethylene Glycol (PEG).
7, pharmaceutical composition according to claim 6 is characterized in that: described plasticizer is a glycerol.
8, pharmaceutical composition according to claim 7 is characterized in that: described solvent comprises distilled water or ethanol or their mixture.
9, pharmaceutical composition according to claim 4, it is characterized in that: described pharmaceutical composition is a liniment, described pharmaceutical carrier is one or more and ethanol and the distilled water in hard ester acid, glycerol, Tween 80, octadecanol, potassium sorbate and the vaseline.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021294380A CN1172680C (en) | 2002-08-26 | 2002-08-26 | Locally applied composite medicine for treating pointed condyloma |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021294380A CN1172680C (en) | 2002-08-26 | 2002-08-26 | Locally applied composite medicine for treating pointed condyloma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1395934A CN1395934A (en) | 2003-02-12 |
| CN1172680C true CN1172680C (en) | 2004-10-27 |
Family
ID=4746241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021294380A Expired - Fee Related CN1172680C (en) | 2002-08-26 | 2002-08-26 | Locally applied composite medicine for treating pointed condyloma |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1172680C (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101199866B (en) * | 2007-12-27 | 2010-09-22 | 高景星 | Soluble cotton fiber containing multiple bioactivity and preparing method thereof |
-
2002
- 2002-08-26 CN CNB021294380A patent/CN1172680C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1395934A (en) | 2003-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1872026A (en) | New medicinal preparation for vagina | |
| CH638402A5 (en) | METHOD FOR PRODUCING A PHARMACEUTICAL FOR INTRODUCTION IN BODY OPENINGS. | |
| CN104922130B (en) | It is a kind of to be used to treat gelling agent of herpes zoster and preparation method thereof | |
| CN1172680C (en) | Locally applied composite medicine for treating pointed condyloma | |
| JP3989188B2 (en) | Bee venom therapy without a bee needle | |
| CN1251738C (en) | Chinese medicine for treating ashen nail and its preparation method | |
| CN1413116A (en) | Pharmaceutical composition for preventing and treating erectile impotence using purified sumsoo extract | |
| CN1221264C (en) | Pharmic compsn. of local administration for treating herpes zoster | |
| RU2349339C1 (en) | Medicine with immune modifying, antivirus, antibacterial antioxidising, membrane stabilising, cartilage and connective tissue growth stimulating effect | |
| CN1350862A (en) | Composition for treating leukoderma | |
| US20060122095A1 (en) | Mucus formulation for mucosal surfaces and uses thereof | |
| US20070032558A1 (en) | Method of treating herpes viral infections using a halogenated hydrocarbon composition | |
| CN1103288A (en) | Local anaesthetic and its preparing method | |
| CN100342913C (en) | Aspirin-containing transdermal pharmaceutical composition for the treatment of calcification | |
| CN1063632C (en) | External use liniment for curing dermatosis | |
| RU2348400C1 (en) | Pharmaceutical preparation for local and external use, based on low-molecular interferon inducer | |
| CN1192358A (en) | Povidone iodine membrane agent | |
| CN1899520A (en) | Chinese medicine composition for removing wart nevus | |
| CN1244398A (en) | Improved tincture with both Chinese and Western medicines for dermatomycosis | |
| CN1092046C (en) | Local medicine composition for healing wound | |
| CN1393221A (en) | Liquid medicine for treating acne | |
| CN1249930A (en) | Diclofenac potassium gel and ointment and the preparation thereof | |
| EP1669064A1 (en) | Composition and method of a topical therapy of neurodermatitis | |
| CN114652708B (en) | Composition for treating deep tissue pain | |
| CN101057973A (en) | Alcohol-free transdermal analgesic composition and processes for manufacture and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: HUNAN ZHONGWEI PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: BEIJING ZHAOYAN NEW DRUG RESEARCH CENTER Effective date: 20091204 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20091204 Address after: Li Yu Industrial Park, Tianyuan District, Zhuzhou, Hunan Patentee after: HUNAN ZONWE PHARMACEUTICAL Co.,Ltd. Address before: Beijing City, Fengtai science and Technology Park Haiying Road No. nine Patentee before: Beijing Zhaoyan New Drug Research Center |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20041027 Termination date: 20210826 |